A Study to Investigate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy With GenSci122 in Participants With Advanced Solid Tumors

NCT06772415 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

163

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumor

Interventions

DRUG: GenSci122 tablet 50mg
DRUG: GenSci122 tablet 250mg

Sponsor

Changchun GeneScience Pharmaceutical Co., Ltd.